Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma
Abstract Introduction Splenic marginal zone lymphoma (SMZL) is a rare low-malignant Non-Hodgkin lymphoma (NHL), in which immune mediated paraneoplastic phenomena such as autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia (ITP) and C1 esterase inhibitor deficiency are relatively common....
Gespeichert in:
| Veröffentlicht in: | Thrombosis research 2014-11, Vol.134 (5), p.980-984 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 984 |
|---|---|
| container_issue | 5 |
| container_start_page | 980 |
| container_title | Thrombosis research |
| container_volume | 134 |
| creator | Gebhart, J Lechner, K Skrabs, C Sliwa, T Müldür, E Ludwig, H Nösslinger, T Vanura, K Stamatopoulos, K Simonitsch-Klupp, I Chott, A Quehenberger, P Mitterbauer-Hohendanner, G Pabinger, I Jäger, U Geissler, K |
| description | Abstract Introduction Splenic marginal zone lymphoma (SMZL) is a rare low-malignant Non-Hodgkin lymphoma (NHL), in which immune mediated paraneoplastic phenomena such as autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia (ITP) and C1 esterase inhibitor deficiency are relatively common. Materials and Methods We performed a multicenter retrospective study in 70 patients on the prevalence and clinical features of antiphospholipid antibodies (aPLA) in SMZL. Results and Conclusions Nine patients (13%) had the diagnosis of a lupus anticoagulant (LA). The occurrence of venous thromboembolic events was significantly higher in LA positive patients compared to LA negative patients (4/9 [44%] vs 5/61 [8%], p = 0.002), especially within 12 months after splenectomy (3/6 [50%] vs 2/28 [7%], p = 0.007). None of the patients with LA had a persistent complete remission of LA after splenectomy, but complete remission of LA was achieved in 2/2 patients after rituximab-bendamustine immuno-chemotherapy. In conclusion, our data show a relatively high prevalence of aPLA in SMZL and an increased risk of postsplenectomy thrombosis in these patients. The fact that rituximab-bendamustine was effective for eradicating LA may be considered as an argument for using immuno-chemotherapy as first line therapy in SMZL patients with LA. |
| doi_str_mv | 10.1016/j.thromres.2014.08.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1629972475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0049384814004575</els_id><sourcerecordid>1629972475</sourcerecordid><originalsourceid>FETCH-LOGICAL-c633t-158d40d24221b8f215403330de2ae3a37317b15cacf0b87a0133a44e79183ba3</originalsourceid><addsrcrecordid>eNqFkU9v2zAMxYVhxZr--QqFj7vYJSU5li_Dhq7tBgToob0LssykymzLk-wC6aef0qQ77LKTKODxke9Hxq4QCgRcXm-L6Tn4PlAsOKAsQBXA8QNboKrqnMuKf2QLAFnnQkl1ys5i3AJghXX5iZ3yMjUBlAv2fTWPc8zMMDnrzWbuUpV-bfZm3_joYuaGLI4dDc5mvQkbN5gue_UDZd2uH599by7Yydp0kS6P7zl7urt9uvmRrx7uf958W-V2KcSUY6laCS2XnGOj1hxLCUIIaIkbEkZUAqsGS2vsGhpVGUAhjJRU1ahEY8Q5-3ywHYP_PVOcdO-ipS7tTH6OGpe8rquUvUzS5UFqg48x0FqPwaXldxpB7wHqrX4HqPcANSidAKbGq-OMuemp_dv2TiwJvh4ElIK-OAo6WkeDpdYFspNuvfv_jC__WNjOJbqm-0U7ils_h4Q45dGRa9CP-zPur4gyVWVK9wcBd5nA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1629972475</pqid></control><display><type>article</type><title>Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Gebhart, J ; Lechner, K ; Skrabs, C ; Sliwa, T ; Müldür, E ; Ludwig, H ; Nösslinger, T ; Vanura, K ; Stamatopoulos, K ; Simonitsch-Klupp, I ; Chott, A ; Quehenberger, P ; Mitterbauer-Hohendanner, G ; Pabinger, I ; Jäger, U ; Geissler, K</creator><creatorcontrib>Gebhart, J ; Lechner, K ; Skrabs, C ; Sliwa, T ; Müldür, E ; Ludwig, H ; Nösslinger, T ; Vanura, K ; Stamatopoulos, K ; Simonitsch-Klupp, I ; Chott, A ; Quehenberger, P ; Mitterbauer-Hohendanner, G ; Pabinger, I ; Jäger, U ; Geissler, K</creatorcontrib><description>Abstract Introduction Splenic marginal zone lymphoma (SMZL) is a rare low-malignant Non-Hodgkin lymphoma (NHL), in which immune mediated paraneoplastic phenomena such as autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia (ITP) and C1 esterase inhibitor deficiency are relatively common. Materials and Methods We performed a multicenter retrospective study in 70 patients on the prevalence and clinical features of antiphospholipid antibodies (aPLA) in SMZL. Results and Conclusions Nine patients (13%) had the diagnosis of a lupus anticoagulant (LA). The occurrence of venous thromboembolic events was significantly higher in LA positive patients compared to LA negative patients (4/9 [44%] vs 5/61 [8%], p = 0.002), especially within 12 months after splenectomy (3/6 [50%] vs 2/28 [7%], p = 0.007). None of the patients with LA had a persistent complete remission of LA after splenectomy, but complete remission of LA was achieved in 2/2 patients after rituximab-bendamustine immuno-chemotherapy. In conclusion, our data show a relatively high prevalence of aPLA in SMZL and an increased risk of postsplenectomy thrombosis in these patients. The fact that rituximab-bendamustine was effective for eradicating LA may be considered as an argument for using immuno-chemotherapy as first line therapy in SMZL patients with LA.</description><identifier>ISSN: 0049-3848</identifier><identifier>EISSN: 1879-2472</identifier><identifier>DOI: 10.1016/j.thromres.2014.08.021</identifier><identifier>PMID: 25201005</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Aged ; Antibodies, Monoclonal, Murine-Derived - therapeutic use ; Antineoplastic Agents - therapeutic use ; Antiphospholipid antibodies ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Immunotherapy ; Lupus anticoagulant ; Lupus Coagulation Inhibitor - analysis ; Lymphoma, B-Cell, Marginal Zone - complications ; Lymphoma, B-Cell, Marginal Zone - pathology ; Lymphoma, B-Cell, Marginal Zone - therapy ; Male ; Middle Aged ; Retrospective Studies ; Rituximab ; SMZL ; Spleen - pathology ; Splenectomy ; Splenic marginal zone lymphoma ; Splenic Neoplasms - complications ; Splenic Neoplasms - pathology ; Splenic Neoplasms - therapy ; Thrombosis ; Thrombosis - complications ; Treatment Outcome</subject><ispartof>Thrombosis research, 2014-11, Vol.134 (5), p.980-984</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c633t-158d40d24221b8f215403330de2ae3a37317b15cacf0b87a0133a44e79183ba3</citedby><cites>FETCH-LOGICAL-c633t-158d40d24221b8f215403330de2ae3a37317b15cacf0b87a0133a44e79183ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.thromres.2014.08.021$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25201005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gebhart, J</creatorcontrib><creatorcontrib>Lechner, K</creatorcontrib><creatorcontrib>Skrabs, C</creatorcontrib><creatorcontrib>Sliwa, T</creatorcontrib><creatorcontrib>Müldür, E</creatorcontrib><creatorcontrib>Ludwig, H</creatorcontrib><creatorcontrib>Nösslinger, T</creatorcontrib><creatorcontrib>Vanura, K</creatorcontrib><creatorcontrib>Stamatopoulos, K</creatorcontrib><creatorcontrib>Simonitsch-Klupp, I</creatorcontrib><creatorcontrib>Chott, A</creatorcontrib><creatorcontrib>Quehenberger, P</creatorcontrib><creatorcontrib>Mitterbauer-Hohendanner, G</creatorcontrib><creatorcontrib>Pabinger, I</creatorcontrib><creatorcontrib>Jäger, U</creatorcontrib><creatorcontrib>Geissler, K</creatorcontrib><title>Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma</title><title>Thrombosis research</title><addtitle>Thromb Res</addtitle><description>Abstract Introduction Splenic marginal zone lymphoma (SMZL) is a rare low-malignant Non-Hodgkin lymphoma (NHL), in which immune mediated paraneoplastic phenomena such as autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia (ITP) and C1 esterase inhibitor deficiency are relatively common. Materials and Methods We performed a multicenter retrospective study in 70 patients on the prevalence and clinical features of antiphospholipid antibodies (aPLA) in SMZL. Results and Conclusions Nine patients (13%) had the diagnosis of a lupus anticoagulant (LA). The occurrence of venous thromboembolic events was significantly higher in LA positive patients compared to LA negative patients (4/9 [44%] vs 5/61 [8%], p = 0.002), especially within 12 months after splenectomy (3/6 [50%] vs 2/28 [7%], p = 0.007). None of the patients with LA had a persistent complete remission of LA after splenectomy, but complete remission of LA was achieved in 2/2 patients after rituximab-bendamustine immuno-chemotherapy. In conclusion, our data show a relatively high prevalence of aPLA in SMZL and an increased risk of postsplenectomy thrombosis in these patients. The fact that rituximab-bendamustine was effective for eradicating LA may be considered as an argument for using immuno-chemotherapy as first line therapy in SMZL patients with LA.</description><subject>Aged</subject><subject>Antibodies, Monoclonal, Murine-Derived - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antiphospholipid antibodies</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Lupus anticoagulant</subject><subject>Lupus Coagulation Inhibitor - analysis</subject><subject>Lymphoma, B-Cell, Marginal Zone - complications</subject><subject>Lymphoma, B-Cell, Marginal Zone - pathology</subject><subject>Lymphoma, B-Cell, Marginal Zone - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>SMZL</subject><subject>Spleen - pathology</subject><subject>Splenectomy</subject><subject>Splenic marginal zone lymphoma</subject><subject>Splenic Neoplasms - complications</subject><subject>Splenic Neoplasms - pathology</subject><subject>Splenic Neoplasms - therapy</subject><subject>Thrombosis</subject><subject>Thrombosis - complications</subject><subject>Treatment Outcome</subject><issn>0049-3848</issn><issn>1879-2472</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v2zAMxYVhxZr--QqFj7vYJSU5li_Dhq7tBgToob0LssykymzLk-wC6aef0qQ77LKTKODxke9Hxq4QCgRcXm-L6Tn4PlAsOKAsQBXA8QNboKrqnMuKf2QLAFnnQkl1ys5i3AJghXX5iZ3yMjUBlAv2fTWPc8zMMDnrzWbuUpV-bfZm3_joYuaGLI4dDc5mvQkbN5gue_UDZd2uH599by7Yydp0kS6P7zl7urt9uvmRrx7uf958W-V2KcSUY6laCS2XnGOj1hxLCUIIaIkbEkZUAqsGS2vsGhpVGUAhjJRU1ahEY8Q5-3ywHYP_PVOcdO-ipS7tTH6OGpe8rquUvUzS5UFqg48x0FqPwaXldxpB7wHqrX4HqPcANSidAKbGq-OMuemp_dv2TiwJvh4ElIK-OAo6WkeDpdYFspNuvfv_jC__WNjOJbqm-0U7ils_h4Q45dGRa9CP-zPur4gyVWVK9wcBd5nA</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Gebhart, J</creator><creator>Lechner, K</creator><creator>Skrabs, C</creator><creator>Sliwa, T</creator><creator>Müldür, E</creator><creator>Ludwig, H</creator><creator>Nösslinger, T</creator><creator>Vanura, K</creator><creator>Stamatopoulos, K</creator><creator>Simonitsch-Klupp, I</creator><creator>Chott, A</creator><creator>Quehenberger, P</creator><creator>Mitterbauer-Hohendanner, G</creator><creator>Pabinger, I</creator><creator>Jäger, U</creator><creator>Geissler, K</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141101</creationdate><title>Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma</title><author>Gebhart, J ; Lechner, K ; Skrabs, C ; Sliwa, T ; Müldür, E ; Ludwig, H ; Nösslinger, T ; Vanura, K ; Stamatopoulos, K ; Simonitsch-Klupp, I ; Chott, A ; Quehenberger, P ; Mitterbauer-Hohendanner, G ; Pabinger, I ; Jäger, U ; Geissler, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c633t-158d40d24221b8f215403330de2ae3a37317b15cacf0b87a0133a44e79183ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal, Murine-Derived - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antiphospholipid antibodies</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Lupus anticoagulant</topic><topic>Lupus Coagulation Inhibitor - analysis</topic><topic>Lymphoma, B-Cell, Marginal Zone - complications</topic><topic>Lymphoma, B-Cell, Marginal Zone - pathology</topic><topic>Lymphoma, B-Cell, Marginal Zone - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>SMZL</topic><topic>Spleen - pathology</topic><topic>Splenectomy</topic><topic>Splenic marginal zone lymphoma</topic><topic>Splenic Neoplasms - complications</topic><topic>Splenic Neoplasms - pathology</topic><topic>Splenic Neoplasms - therapy</topic><topic>Thrombosis</topic><topic>Thrombosis - complications</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gebhart, J</creatorcontrib><creatorcontrib>Lechner, K</creatorcontrib><creatorcontrib>Skrabs, C</creatorcontrib><creatorcontrib>Sliwa, T</creatorcontrib><creatorcontrib>Müldür, E</creatorcontrib><creatorcontrib>Ludwig, H</creatorcontrib><creatorcontrib>Nösslinger, T</creatorcontrib><creatorcontrib>Vanura, K</creatorcontrib><creatorcontrib>Stamatopoulos, K</creatorcontrib><creatorcontrib>Simonitsch-Klupp, I</creatorcontrib><creatorcontrib>Chott, A</creatorcontrib><creatorcontrib>Quehenberger, P</creatorcontrib><creatorcontrib>Mitterbauer-Hohendanner, G</creatorcontrib><creatorcontrib>Pabinger, I</creatorcontrib><creatorcontrib>Jäger, U</creatorcontrib><creatorcontrib>Geissler, K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gebhart, J</au><au>Lechner, K</au><au>Skrabs, C</au><au>Sliwa, T</au><au>Müldür, E</au><au>Ludwig, H</au><au>Nösslinger, T</au><au>Vanura, K</au><au>Stamatopoulos, K</au><au>Simonitsch-Klupp, I</au><au>Chott, A</au><au>Quehenberger, P</au><au>Mitterbauer-Hohendanner, G</au><au>Pabinger, I</au><au>Jäger, U</au><au>Geissler, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma</atitle><jtitle>Thrombosis research</jtitle><addtitle>Thromb Res</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>134</volume><issue>5</issue><spage>980</spage><epage>984</epage><pages>980-984</pages><issn>0049-3848</issn><eissn>1879-2472</eissn><abstract>Abstract Introduction Splenic marginal zone lymphoma (SMZL) is a rare low-malignant Non-Hodgkin lymphoma (NHL), in which immune mediated paraneoplastic phenomena such as autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia (ITP) and C1 esterase inhibitor deficiency are relatively common. Materials and Methods We performed a multicenter retrospective study in 70 patients on the prevalence and clinical features of antiphospholipid antibodies (aPLA) in SMZL. Results and Conclusions Nine patients (13%) had the diagnosis of a lupus anticoagulant (LA). The occurrence of venous thromboembolic events was significantly higher in LA positive patients compared to LA negative patients (4/9 [44%] vs 5/61 [8%], p = 0.002), especially within 12 months after splenectomy (3/6 [50%] vs 2/28 [7%], p = 0.007). None of the patients with LA had a persistent complete remission of LA after splenectomy, but complete remission of LA was achieved in 2/2 patients after rituximab-bendamustine immuno-chemotherapy. In conclusion, our data show a relatively high prevalence of aPLA in SMZL and an increased risk of postsplenectomy thrombosis in these patients. The fact that rituximab-bendamustine was effective for eradicating LA may be considered as an argument for using immuno-chemotherapy as first line therapy in SMZL patients with LA.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>25201005</pmid><doi>10.1016/j.thromres.2014.08.021</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0049-3848 |
| ispartof | Thrombosis research, 2014-11, Vol.134 (5), p.980-984 |
| issn | 0049-3848 1879-2472 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1629972475 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Aged Antibodies, Monoclonal, Murine-Derived - therapeutic use Antineoplastic Agents - therapeutic use Antiphospholipid antibodies Female Hematology, Oncology and Palliative Medicine Humans Immunotherapy Lupus anticoagulant Lupus Coagulation Inhibitor - analysis Lymphoma, B-Cell, Marginal Zone - complications Lymphoma, B-Cell, Marginal Zone - pathology Lymphoma, B-Cell, Marginal Zone - therapy Male Middle Aged Retrospective Studies Rituximab SMZL Spleen - pathology Splenectomy Splenic marginal zone lymphoma Splenic Neoplasms - complications Splenic Neoplasms - pathology Splenic Neoplasms - therapy Thrombosis Thrombosis - complications Treatment Outcome |
| title | Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A25%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lupus%20anticoagulant%20and%20thrombosis%20in%20splenic%20marginal%20zone%20lymphoma&rft.jtitle=Thrombosis%20research&rft.au=Gebhart,%20J&rft.date=2014-11-01&rft.volume=134&rft.issue=5&rft.spage=980&rft.epage=984&rft.pages=980-984&rft.issn=0049-3848&rft.eissn=1879-2472&rft_id=info:doi/10.1016/j.thromres.2014.08.021&rft_dat=%3Cproquest_cross%3E1629972475%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1629972475&rft_id=info:pmid/25201005&rft_els_id=1_s2_0_S0049384814004575&rfr_iscdi=true |